Literature DB >> 2476904

Increased alpha 2-macroglobulin in diabetes: a hyperglycemia related phenomenon associated with reduced antithrombin III activity.

A Ceriello1, D Giugliano, A Quatraro, A Stante, P Dello Russo, R Torella.   

Abstract

Increased alpha 2-macroglobulin (alpha 2M) activity and concentration, and decreased antithrombin III (ATIII) plasma concentration are reported in diabetic subjects. In diabetes an inverse correlation between ATIII activity and blood glucose, HbA1, alpha 2M activity and alpha 2M concentration, and a direct correlation between both alpha 2M activity and alpha 2M concentration with blood glucose and HbA1 are found. Moreover, a direct correlation between alpha 2M activity and alpha 2M concentration fails. In both diabetic and normal subjects induced hyperglycemia increases alpha 2M activity and alpha 2M concentration reduces ATIII activity, while ATIII concentration is not affected. These data which show that hyperglycemia may increase alpha 2M molecule levels while altering only the biological function of ATIII, provide evidence that hyperglycemia may decrease, directly, the biological function of some proteins and may condition the levels of some risk factors for the development of diabetic complications such as alpha 2M.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2476904     DOI: 10.1007/bf02581366

Source DB:  PubMed          Journal:  Acta Diabetol Lat        ISSN: 0001-5563


  18 in total

1.  Antithrombin 3 deficiency in maturity onset diabetes mellitus and atherosclerosis.

Authors:  R N Banerjee; A L Sahni; V Kumar; M Arya
Journal:  Thromb Diath Haemorrh       Date:  1974-05-15

2.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

3.  Non-enzymatic glycosylation reduces antithrombin III activity.

Authors:  A Ceriello; F Curcio; P Dello Russo; D Giugliano
Journal:  Thromb Haemost       Date:  1984-12-29       Impact factor: 5.249

Review 4.  Alpha 2-macroglobulin and antithrombin-heparin cofactor: modulators of hemostatic and inflammatory reactions. Alpha 2-macroglobulin.

Authors:  P C Harpel; R D Rosenberg
Journal:  Prog Hemost Thromb       Date:  1976

5.  Soluble fibrin complexes and fibrinogen heterogeneity in diabetes mellitus.

Authors:  E B Tsianos; N E Stathakis
Journal:  Thromb Haemost       Date:  1980-12-19       Impact factor: 5.249

6.  Inhibition of heparin-catalyzed human antithrombin III activity by nonenzymatic glycosylation. Possible role in fibrin deposition in diabetes.

Authors:  M Brownlee; H Vlassara; A Cerami
Journal:  Diabetes       Date:  1984-06       Impact factor: 9.461

7.  Metabolic control may alter antithrombin III activity but not its plasma concentration in diabetes: a possible role for nonenzymatic glycosylation.

Authors:  A Ceriello; D Giugliano; P Dello Russo; A Tirelli; N Passariello; S Sgambato
Journal:  Diabetes Care       Date:  1986 Jan-Feb       Impact factor: 19.112

8.  Daily rapid blood glucose variations may condition antithrombin III biologic activity but not its plasma concentration in insulin-dependent diabetes. A possible role for labile non-enzymatic glycation.

Authors:  A Ceriello; D Giugliano; A Quatraro; A Stante; G Consoli; P Dello Russo; F D'Onofrio
Journal:  Diabete Metab       Date:  1987-02

9.  Induced hyperglycemia alters antithrombin III activity but not its plasma concentration in healthy normal subjects.

Authors:  A Ceriello; D Giugliano; A Quatraro; G Consoli; A Stante; P Dello Russo; F D'Onofrio
Journal:  Diabetes       Date:  1987-03       Impact factor: 9.461

10.  Heparin preserves antithrombin III biological activity from hyperglycemia-induced alterations in insulin-dependent diabetics.

Authors:  A Ceriello; D Giugliano; A Quatraro; A Stante; G Consoli; P Dello Russo; F D'Onofrio
Journal:  Haemostasis       Date:  1986
View more
  5 in total

Review 1.  Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects.

Authors:  A Ceriello
Journal:  Diabetologia       Date:  1993-11       Impact factor: 10.122

2.  Diabetic dyslipidemia and exercise alter the plasma low-density lipoproteome in Yucatan pigs.

Authors:  Matthew R Richardson; Xianyin Lai; Joseph L Dixon; Michael Sturek; Frank A Witzmann
Journal:  Proteomics       Date:  2009-05       Impact factor: 3.984

3.  Chronic insulin treatment of diabetes does not fully normalize alterations in the retinal transcriptome.

Authors:  Georgina V Bixler; Heather D Vanguilder; Robert M Brucklacher; Scot R Kimball; Sarah K Bronson; Willard M Freeman
Journal:  BMC Med Genomics       Date:  2011-05-15       Impact factor: 3.063

Review 4.  Type 1 Diabetes Mellitus in the SARS-CoV-2 Pandemic: Oxidative Stress as a Major Pathophysiological Mechanism Linked to Adverse Clinical Outcomes.

Authors:  Aikaterini Kountouri; Emmanouil Korakas; Ignatios Ikonomidis; Athanasios Raptis; Nikolaos Tentolouris; George Dimitriadis; Vaia Lambadiari
Journal:  Antioxidants (Basel)       Date:  2021-05-09

Review 5.  Coagulatory Defects in Type-1 and Type-2 Diabetes.

Authors:  Amélie I S Sobczak; Alan J Stewart
Journal:  Int J Mol Sci       Date:  2019-12-16       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.